European Neuropsychopharmacology | 2021

W57. MENTAL HEALTH DATA COLLECTION IN THE ESTONIAN BIOBANK: INSTRUMENTS, METHODOLOGY AND PRELIMINARY RESULTS

 
 
 
 
 
 
 

Abstract


Background: Background: Common psychiatric disorders are clinically heterogeneous and often display many overlapping symptoms as well as comorbidity across psychiatric disorders, hence complicating the genetic investigation of these disorders. To facilitate new discoveries and gain better understanding of the genetics of psychiatric problems, large well-phenotyped biobank samples are greatly needed. The Estonian Biobank (EstBB;N=200,000) is a data-rich national biobank that joins genomic, biomarker, electronic health record (EHR), national registry and questionnaire data to significantly advance the current knowledge of the genetic underpinnings of complex and rare diseases. We aimed to expand the EstBB database with rich phenotypic questionnaire-based information on a broad set of symptoms of common psychiatric disorders and related phenotypes. Methods: Methods: We compiled an online questionnaire “Wellbeing and mental health” which included self-report brief screening instruments to capture a broad range of symptoms on current and/or lifetime depression, anxiety disorders, mania, post-traumatic stress disorder, eating disorders, attention deficit/hyperactivity disorder, psychotic experiences, suicidal thoughts and behavior, cognition, substance (ab)use, problematic gambling and related risk- and protective factors, such as childhood adversity, stressful life events, social support, lifestyle, sociodemographic factors and life satisfaction. In addition, the participants were asked about the side effects, discontinuation and switching of medications prescribed for a mental health problem in their lifetime. Since the start of the data collection coincided with the peak of the second COVID-19 wave in Estonia, we included items related to current perceived stress, burnout and change in mental health during the pandemic. When selecting instruments, preference was given based on 1) reliability and validity of the instruments;2) whether an Estonian adaptation and/or validation has been conducted;3) application in other large biobanks (e.g. the UK Biobank) for future harmonization or replication;4) short length. Results: Results: The invitations to participate in the online mental health study were e-mailed out to all living EstBB participants with available e-mail addresses (N=184,622), followed by two e-mail reminders. The active data collection phase spanned over three months from March to May 2021. The preliminary response rate was 46.7% (N = 86,222) out of all who were contacted. We will present preliminary results on the comparison of respondents and non-respondents based on demographic data, psychiatric diagnoses in EHR and psychiatric polygenic risk scores. Discussion: Discussion: We have significantly expanded the EstBB resource with phenotypic information on a broad range of psychiatric symptoms and related phenotypes to facilitate future research in psychiatric genetics. Disclosure: Nothing to disclose.

Volume 51
Pages None
DOI 10.1016/j.euroneuro.2021.08.142
Language English
Journal European Neuropsychopharmacology

Full Text